EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial

Raquel González iD, Anna Goncé iD, Mª Del Mar Gil iD, Edurne Mazarico, Elena Ferriols-Pérez, Paloma Toro, Elisa Llurba, Elisa Saéz, Miguel Ángel Rodríguez-Zambrano, Laura García-Otero, Marta López, Belén Santacruz und 11 weitere

Acta Obstetricia et Gynecologica Scandinavica · 2024

DOI: 10.1111/aogs.14745 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2024. Verfasst von Raquel González und 22 weiteren Autor:innen. Beteiligte Einrichtung: ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pregnant women have an increased risk of severe COVID‐19. Evaluation of drugs with a safety reproductive toxicity profile is a priority. At the beginning of the pandemic, hydroxychloroquine (HCQ) was recommended for COVID‐19 treatment. Material and methods A randomized, double‐blind, placebo‐controlled clinical trial was conducted in eight teaching hospitals in Spain to evaluate the safety and efficacy of HCQ in reducing viral shedding and preventing COVID‐19 progression. Pregnant and postpartum women with a positive SARS‐CoV‐2 PCR (with or without mild COVID‐19 signs/symptoms) and a normal electrocardiogram were randomized to receive either HCQ orally (400 mg/day for 3 days and 200 mg/day for 11 days) or placebo. PCR and electrocardiogram were repeated at day 21 after treatment start. Enrollment was stopped before reaching the target sample due to low recruitment rate.

Trial registration

EudraCT #: 2020‐001587‐29, on April 2, 2020. Clinical trials.gov # NCT04410562, registered on June 1, 2020.

Results

A total of 116 women (75 pregnant and 41 post‐partum) were enrolled from May 2020 to June 2021. The proportion of women with a positive SARS‐CoV‐2 PCR at day 21 was lower in the HCQ group (21.8%, 12/55) than in the placebo group (31.6%, 18/57), although the difference was not statistically significant ( P = 0.499). No differences were observed in COVID‐19 progression, adverse events, median change in QTc, hospital admissions, preeclampsia or poor pregnancy and perinatal outcomes between groups.

Conclusions

HCQ was found to be safe in pregnant and postpartum women with asymptomatic or mild SARS‐CoV‐2 infection. Although the prevalence of infection was decreased in the HCQ group, the statistical power was insufficient to confirm the potential beneficial effect of HCQ for COVID‐19 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19FemaleHumansPregnancySARS-CoV-2HydroxychloroquineCOVID-19 Drug TreatmentPostpartum PeriodDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

COVID-19SARS-CoV-2hydroxychloroquinepregnancyrandomized controlled trialwomen

Substanzen

Hydroxychloroquine

Autor:innen und Institutionen

  • ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
  • Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP).
  • Manhiça Health Research Center (CISM), Manhiça, Mozambique.
  • BCNATAL | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
  • Obstetrics and Gynecology Department, Hospital Universitario de Torrejón, Madrid, Spain.
  • School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.

ORCID-Profile: Raquel González, Anna Goncé, Mª Del Mar Gil, Antoni Payà, Mónica Cruz-Lemini, Clara Pons-Duran, Azucena Bardají

Förderung

  • Ministerio de Ciencia e Innovación

Zitieren

APA

González, R., Goncé, A., Gil, M. D. M., Mazarico, E., Ferriols-Pérez, E., Toro, P., Llurba, E., Saéz, E., Rodríguez-Zambrano, M. Á., García-Otero, L., López, M., Santacruz, B., Román, M. Á., Payà, A., Alonso, S., Cruz-Lemini, M., Pons-Duran, C., Herrera, L. B., Chen, H., …, & COVID-Preg research group (2024). Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14745

Vancouver

González R, Goncé A, Gil MDM, Mazarico E, Ferriols-Pérez E, Toro P, et al. Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial. Acta Obstetricia et Gynecologica Scandinavica. 2024. doi:10.1111/aogs.14745

BibTeX
@article{Gonzlez2024,
  author = {González, Raquel and Goncé, Anna and Gil, Mª Del Mar and Mazarico, Edurne and Ferriols-Pérez, Elena and Toro, Paloma and Llurba, Elisa and Saéz, Elisa and Rodríguez-Zambrano, Miguel Ángel and García-Otero, Laura and López, Marta and Santacruz, Belén and Román, Mª Ángeles and Payà, Antoni and Alonso, Sofia and Cruz-Lemini, Mónica and Pons-Duran, Clara and Herrera, Luis Bernardo and Chen, Haily and Bardají, Azucena and Quintó, Llorenç and Menendez, Clara and COVID-Preg research group, COVID-Preg research group},
  title = {Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2024},
  doi = {10.1111/aogs.14745}
}
Kostenlos starten →